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Zhi Jiang et al.2021. Introduction
Viral infectious diseases have caused constant threat to human
health and the prevention and treatment of viral diseases are a
global public health challenge. Hepatitis C virus (HCV) is a single-
stranded, positive-sense RNA virus. There was an estimated 170
million people worldwide infected with HCV, and many of them
died from HCV-related liver diseases1. In the early years, the
combination of PEG-interferon and ribavirin was the only treat-
ment for HCV-infected patients with 40%–50% effectiveness2.
Direct-acting antiviral agents (DAA) such as HCV NS3/4A
protease inhibitors telaprevir and boceprevir have signiﬁcantly
increased the efﬁcacy in combination with PEG-interferon and
ribavirin3. Recently, a new generation of DAAs has become
available and currently the interferon-free combination therapy
of sofosbuvir (NS5B polymerase inhibitor)4, ledipasvir (NS5A
replication complex inhibitor)5 and ribavirin has resulted in a cure
rate up to 100% among patients infected with HCV. All of the four
marketing drugs, telaprevir, boceprevir, sofosbuvir and ledipasvir
were targeting on HCV proteins. However, resistant strains may
eventually arise6.
The single-stranded RNA virus EV71 belongs to the Picorna-
viridae family and usually causes a mild syndrome such as hand-
foot-mouth disease (HFMD) and herpangina7,8. However, some
young children infected by EV71 have developed fatal neurolo-
gical complications such as aseptic meningitis, encephalitis,
poliomyelitis-like paralysis and even death9. EV71 infection has
been reported worldwide, especially in the Asia-Paciﬁc region10.
Currently, there was no effective approved antiviral available for
the prevention or treatment of EV71 infection. Supportive therapy
is the primary treatment option for severe cases11–13.
Given the limited efﬁciency, side effects and drug resistance of
these antiviral treatments, continued research is required to
develop antiviral drugs with new mechanisms of action. Recently,
cellular factors have emerged as useful targets for antiviral therapy
and strengthening cellular defense mechanism may be an approach
to develop broad-spectrum antivirals. APOBEC3G (Human apo-
lipoprotein B mRNA–editing enzyme catalytic polypeptide-like
3G, hA3G) was initially identiﬁed as a host cellular restriction
factor of HIV-1 by Sheehy et al.14. In addition, Peng15 has
demonstrated that the introduction of external hA3G into HCV-
infected Huh7.5 cells effectively inhibited HCV replication. The
small molecule compound IMB-26 (3, 4, 5-trimethoxyphenyl-3-(2-
bromopropionamido)-4-methoxybenzamide) (Fig. 1) was identi-
ﬁed as a stabilizer of hA3G and it was effective against HCV
replication in vitro (IC50¼1.4670.62 μmol/L, CC50¼11.847
2.87 μmol/L). Our previous work has described a series of
substituted N-aryl benzamide compounds such as IMB-1f andFigure 1 Chemical structures of tIMB-1g (Fig. 1) as anti-HCV agents with the IC50 values ranging
from 1.00 μmol/L to 2.00 μmol/L16. In addition, hA3G was also
found to be active against other viruses, such as HBV and
inﬂuenza virus17,18. Although there has been no report about the
relationship between hA3G and EV71, in our laboratory, a series
of novel N-phenylbenzamide derivatives were evaluated for their
anti-EV71 activity (IC50¼5.7–12.0 μmol/L)19. The results showed
that IMB-1e (Fig. 1) was the most active compound against EV71.
These results prompted us to further optimize the N-phenyl-
benzamide scaffold to discover more potent antiviral agents. The
optimization began with the alkylation of the amino group by a
methyl group at the C3-positon on the benzene ring A, and then
lipophilic substituents were introduced to the benzene ring B.
Meanwhile, we replaced methoxy group at the C4-positon on the
benzene ring A with hydroxyl, methyl groups or a hydrogen atom.
In addition, to identify the importance of the amide linker between
the two aromatic rings A and B, a series of N-phenylacetophenone
compounds were also studied. The antiviral activity of the
synthesized compounds against HCV and EV71 was evaluated.2. Results and discussion
2.1. Chemistry
To discover more potent hA3G antiviral agents based on the
N-phenylbenzamide scaffold, we designed a series of novel
N-phenylbenzamide derivatives. Our previous work has demon-
strated that the amino group at the C3-position on the benzene ring
A was crucial for antiviral activity. However, due to the
cytotoxicity associated with the amino group, the alkylation
products of the amino group at the C3-position on the benzene
ring A were designed. Meanwhile, our previous results indicated
that lipophilic substituents on the benzene ring B would exhibit
strong biological activity. Thus, we introduced some lipophilic
substituents into the benzene ring B. The amide linker between the
two aromatic rings was unstable in vivo, and the hydrolysis of the
amide-liker resulted in a loss of antiviral activity. Hence, we
inserted a CH2 group between the CO and NH groups to increase
the stability of the amide linker. Additionally, we replaced
methoxy group with hydroxyl, methyl groups or a hydrogen atom
to investigate the inﬂuence of the methoxy group at the C4-positon
on the benzene ring A for antiviral activity.
A series of N-phenylbenzamide analogs were prepared accord-
ing to the procedures outlined in Schemes 1 and 2. Compounds
21–34 were synthesized using commercially available 4-methoxy-
3-nitrobenzoic acid 1 as the starting material. It was converted into
the corresponding benzoyl chloride 2, which was condensed with ahe antiviral active compounds.
Scheme 1 Synthetic route for target compounds 22–36. Reagents and conditions: (a) SOCl2, reﬂux; (b) anilines, TEA, r.t.; (c) H2, 10% dry Pd/C,
r.t.; (d) CH3CH2COCl, TEA, r.t.; (e) 40% HCHO, r.t.; (f) BBr3, 78 1C.
Scheme 2 Synthetic route for target compounds 41–44. Reagents and conditions: (a) anilines, DIC, HOBt, r.t.; (b) CH3CH2COCl, TEA, r.t.;
(c) CH3I, K2CO3, 50 1C.
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the intermediate compounds 3–11. After the nitro groups of the
intermediates 3–11 were reduced by hydrogen over 10% dry Pd/C,
the amino groups at the C3-positon on the benzene ring A were
then acylated by propionyl chloride to afford the 3-propionamido
compounds 21–27 or condensed with formaldehyde to afford the
3-methylamido compounds 28–34.
To convert the methoxy group to the hydroxyl group at the C4-
position on the benzene ring A, compound 21 or 23 was
demethylated using BBr3 at 78 1C to afford the 4-hydroxyl
compounds 35 and 36.
To alter the methoxy group to the methyl group or a hydrogen
atom at the C4-position on the benzene ring A, compounds 41–44
were prepared using 3-aminobenzoic acid 37 or 3-amino-4-
methylbenzoic acid 38 as the starting materials, which was condensed
with anilines using diisopropylcarbodiimide (DIC) as a couplingreagent and N-hydroxybenzotriazole (HOBt) as an activating reagent
to yield the intermediates 39 or 40. The amino groups were then
acylated by propionyl chloride to afford the desired compounds 41
and 43, or alkylated by iodomethane (CH3I) to afford the desired
compounds 42 and 44.
To study the importance of the amide linker between the two
aromatic rings A and B, we designed a series of N-phenylace-
tophenone compounds according to the procedures outlined in
Schemes 3 and 4. The starting material 1-(4-methoxy-3-nitro-
phenyl) ethanone 45 was reduced by hydrogen over 10% dry Pd/
C and then acylated by propionyl chloride to yield the inter-
mediate 47, which was converted to bromo compound 48 by
NBS. The bromo compound was then reacted with anilines to
afford the N-phenylacetophenone products 49 and 50. The
synthesis of the alkylation products of the amino group was
conducted according to the procedure shown in Scheme 4.
Scheme 3 Synthetic route for target compounds 49 and 50. Reagents and conditions: (a) H2, 10% dry Pd/C, r.t.; (b) CH3CH2COCl, TEA, r.t.; (c)
NBS, p-TSA, reﬂux; (d) anilines, NaHCO3, r.t.
Scheme 4 Synthetic route for target compounds 54 and 55. Reagents and conditions: (a) NBS, p-TSA, reﬂux; (b) anilines, NaHCO3, r.t.; (c) H2,
10% dry Pd/C, 40% HCHO, r.t.
Table 1 Anti-HCV activity and cytotoxicity of the synthe-
sized compounds.a
Compd. IC50 (μmol/L) CC50 (μmol/L) SI
Zhi Jiang et al.204Firstly, the starting material 45 was converted into the bromo
compound 51, which was then coupled with anilines to yield the
intermediates 52 and 5320. The desired compounds 54 and 55
were obtained using a one-pot procedure from the corresponding
nitro aryls21.23 0.5770.00 30.6571.25 53.4
25 2.3670.12 122.2472.60 51.8
31 32.0072.14 56.6374.20 1.8
33 34.6073.10 39.9677.25 1.20
41 7.1272.48 4200 428
42 19.5177.18 163.7379.84 8.00
VX-950 0.0170.00 21.2774.70 2331
aAll data were average values from three independent assays.2.2. Evaluation of anti-HCV activity
The antiviral activity of the synthesized compounds against HCV
was tested in infected Huh7.5 cells using the RT-PCR method, and
VX-950 (telaprevir), a NS3/4A protease inhibitor, was used as a
positive control. As shown in Table 1, three compounds 23, 25 and
41 showed relatively potent anti-HCV activity with the IC50 values
ranging from 0.57 μmol/L to 7.12 μmol/L. Among these three
compounds, the anti-HCV activity of compound 23 (IC50¼
0.5770.00 μmol/L) was superior to that of the reported com-
pounds IMB-26 (IC50¼1.4670.62 μmol/L), IMB-1f (IC50¼
1.9070.57 μmol/L) and IMB-1f (IC50¼1.0070.05 μmol/L).
The cytotoxicity was lower, and especially the selective index
(SI) of compound 23 was 53.4. But the potency and selectivity of
all the tested compounds against HCV were much lower than that
of the control drug telaprevir.
From the results above, we can observe that compounds 23, 25
and 41 possessing the same substituent (propionamido group) at
the C3-position on the benzene ring A showed higher anti-HCV
activity than those with the methylamino group (31, 33 and 42).
Meanwhile, the substituents of these three compounds at the C40-
position on the benzene B were lipophilic (tert-butyl, cyclohexyl,
and chloro groups). Thus, these indicated that the propionylamino
group at the C3-position on the benzene ring A and lipophilic
groups at the C40-positon on the benzene ring B were the preferred
substituents for the activity against HCV. Among these com-
pounds with the propionamido group at the C3-position on the
benzene ring A, compound 41 without a substituent has decreased
antiviral activity compared with those with a methoxy substituent
(23 and 25).2.3. Evaluation of anti-EV71 activity
The antiviral activity of the synthesized compounds against EV71
(strain SZ-98) were evaluated in Vero cells using the CPE method
and a broad-spectrum picornavirus inhibitor, pirodavir, was used
as a positive control. The results of antiviral activity are
summarized in Table 2. The IC50 values of several N-phenylben-
zamide derivatives (23, 28, 29, 30, 31 and 42) were lower
than 5.00 μmol/L. Especially, the antiviral activity of 29
(IC50¼0.9570.11 μmol/L) was close to that of the comparator
drug (IC50¼0.16 μmol/L). Moreover, the SI values of compound
28 and 29 were much larger than 20. Unfortunately, the
N-phenylacetophenone compounds 49, 50, 54 and 55 were
inactive against EV71 in this experiment. The result might indicate
that the amide linker between the two aromatic rings A and B was
essential for anti-EV71 activity.
Based on the results of anti-EV71 activity above, the prelimin-
ary structure-activity relationships (SAR) have been established.
The replacement of chlorine at the C40-positon on the benzene ring
B with other lipophilic substituents, such as isopropyl, tert-butyl,
and n-butyl group (22–24) increased the anti-EV71 activity.
However, the N-methyl piperazine derivative (27) did not display
antiviral activity against EV71. So we concluded that lipophilic
substituents on the benzene ring B was crucial to display anti-EV71
Table 2 Anti-EV71 (strain SZ-98) activity and cytotoxicity
of the synthesized compounds.a
Compd. IC50 (μmol/L) TC50 (μmol/L) SI
22 8.4175.94 465.35 47.77
23 3.5370.73 36.2470.00 10.31
24 14.1872.94 36.2470.00 2.56
26 468.79 297.67 –
27 4168.36 291.6070.00 –
28 4.9370.00 110.5070.00 22.41
29 0.9570.11 426.09 427.44
30 3.5671.74 48.29 42.33
31 4.0170.83 34.2370.00 8.58
32 6.8975.00 41.1270.00 5.97
34 16.2672.88 479.07 44.86
35 11.7372.45 100.7970.00 8.59
36 9.1072.06 86.0870.00 –
41 14.1770.00 106.1270.00 7.49
42 4.0770.00 428.5 46.99
43 98.74720.47 196.1070.00 42.00
44 19.6377.42 322.6570.00 16.45
49 422.73 98.31 –
50 420.14 420.14 –
54 82.3070.00 167.11734.70 2.03
55 424.38 73.1070.00 –
Pirodavir 0.1670.00 49.7873.96 306.17
aAll data were average values from three independent assays.
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group were introduced at the C40-positon on the benzene ring B
(26), a decreased activity was observed. In addition, altering the
propionamido group at the C3-postion on the benzene ring A to
the methylamino group (28–34) led to an increase in antiviral
activity. In particular, the activity of the 40-ethyl derivative (29)
was close to that of the comparator drug pirodavir. The replace-
ment of the methoxy group at the C4-positon on the benzene ring
A with a hydroxy group (35 and 36), or a hydrogen atom (42)
increased the antiviral activity. However, when a methyl group
was placed at the C4-position on the benzene ring A (43 and 44),
the antiviral activity was poor.
Because the amide linker was metabolically unstable in vivo, we
inserted a CH2 group between the CO and NH groups of the amide
linker and synthesized four N-phenylacetophenone compounds
(49, 50, 54, 55). But the antiviral activity against EV71 was much
lower than the corresponding N-phenylbenzamide compounds.
The result highlighted the importance of the amide linker in anti-
EV71 activity.3. Conclusions
Our previous work has demonstrated that N-phenylbenzamide
compounds were a class of potential broad-spectrum antiviral
agents. In this paper, a series of novel N-phenylbenzamide and N-
phenylacetophenone compounds with a methylamino group on the
benzene ring A were synthesized. Lipophilic substituents were
introduced at the C40-position on the benzene ring B, or a CH2
group was inserted between the CO and NH groups of the amide
linker, or a methoxy group at the C4-positon on the benzene ring
A was replaced with a hydroxy, a methyl group or a hydrogen
atom. Totally 23 novel analogs were synthesized and evaluated for
their antiviral activity against HCV and EV71 (strain SZ-98).Compounds 23, 25 and 41 exhibited considerable anti-HCV
activity with the IC50 values ranging from 0.57 to 7.12 μmol/L,
and several compounds (23, 28, 29, 30, 31 and 42) exhibited
potent activity against EV71 with IC50 values lower than
5.00 μmol/L. Particularly, the potency of compound 23 was
superior to that of the reported compound IMB-26, IMB-1f and
IMB-1g for anti-HCV activity, and compound 29 displayed the
highest anti-EV71 activity almost comparable to the comparator
drug pirodavir. Their efﬁcacy in vivo and antiviral mechanism will
be further investigated in the future.4. Experimental
4.1. Synthesis and characterization
1H NMR and 13C NMR spectra were recorded in CDCl3 or
DMSO-d6 on a Bruker BioSpin GmbH 400, 500 or 600 spectro-
meter. Chemical shifts were reported in parts per million relative to
tetramethylsilane as an internal standard. High-resolution mass
spectra (HRMS) were obtained on an MDS SCIEX Q-Trap mass
spectrometer. Melting points were determined with an X6 micro-
scope melting point apparatus and uncorrected. All reagents and
solvents were purchased from J&K and Alfa Aesar Chemicals
without puriﬁcation.
4.1.1. General procedure for the synthesis of compounds 12–20
A solution of 1 (2.5 mmol) in SOCl2 (5 mL) was reﬂuxed for 3 h.
The mixture was cooled to ambient temperature and then the
solvent was removed under reduced pressure. Aniline (2.5 mmol)
and TEA (2.5 mmol) were dissolved in dichloromethane (DCM)
(20 mL) and a solution of the acyl chloride above in DCM (5 mL)
was added to the reaction. After the mixture was stirred at room
temperature for 5 h, the reaction was quenched with saturated
aqueous NH4Cl (20 mL), extracted with DCM (20 mL 3), and
washed with brine. The combined organic layers were dried over
Na2SO4 and concentrated under reduced pressure. The residue was
puriﬁed by column chromatography (PE/EA¼10:1, v/v) to give
3–11, which was then dissolved in CH3OH (20 mL) followed by
the addition of 10% dry Pd/C (0.01 mmol). The mixture was
stirred under hydrogen for 4 h. The catalyst was ﬁltered off and the
combined organic solution was concentrated under reduced
pressure to afford the intermediates 12–20.
4.1.2. General procedure for the synthesis of compounds 21–27
To a solution of 12 or 15–20 (2.0 mmol) in DCM (20 mL) was
added TEA (2.0 mmol), and then a solution of propionyl chloride
(3.0 mmol) in DCM (5 mL) was added slowly. After the mixture
was stirred at room temperature for 3 h, the reaction was extracted
with DCM (20 mL 3), and washed with brine. The combined
organic layers were dried under Na2SO4 and concentrated under
reduced pressure. The residue was puriﬁed by column chromato-
graphy (PE/EA¼10:1, v/v) to give 21–27.
N-(4-Iso-propylphenyl)-4-methoxy-3-propionamidobenzamide
(22): a white solid; yield: 89%. m.p: 171–173 1C. 1H NMR
(400 MHz, DMSO-d6): δ 10.03 (s, 1H), 9.18 (s, 1H), 8.51 (s, 1H),
7.75 (dd, J¼8.6, 2.0 Hz, 1H), 7.68–7.64 (m, 2H), 7.21 (d,
J¼8.5 Hz, 2H), 7.15 (d, J¼8.7 Hz, 1H), 3.91 (s, 3H), 2.88–
2.85 (m, 1H), 2.42 (q, J¼7.5 Hz, 2H), 1.20 (d, J¼6.1 Hz, 6H),
1.09 (t, J¼7.5 Hz, 3H). 13C NMR (101 MHz, DMSO-d6): δ
172.72, 165.34, 152.80, 143.92, 137.55, 127.50, 127.36, 126.70,
124.60, 122.65, 120.93, 110.85, 56.45, 33.37, 29.63, 24.45, 10.20.
Zhi Jiang et al.206HR-MS (ESIþ): 341.1857, Calcd. for C20H24N2O3: 341.1859
[MþH]þ.
N-(4-tert-Butylphenyl)-4-methoxy-3-propionamidobenzamide
(23): a white solid; yield: 85%. m.p: 165–166 1C. 1H NMR
(400 MHz, DMSO-d6): δ 10.03 (s, 1H), 9.18 (s, 1H), 8.51 (s, 1H),
7.74 (dd, J¼8.6, 2.2 Hz, 1H), 7.68–7.66 (m, 2H), 7.37–7.34
(m, 2H), 7.15 (d, J¼8.7 Hz, 1H), 3.92 (s, 3H), 2.42 (q, J¼7.5 Hz,
2H), 1.29 (s, 9H), 1.09 (t, J¼7.5 Hz, 3H). 13C NMR (101 MHz,
DMSO-d6): δ 172.73, 165.36, 152.80, 146.16, 137.23, 127.50,
127.36, 125.60, 124.60, 122.66, 120.59, 110.84, 56.45, 34.50,
31.69, 29.63, 10.20. HR-MS (ESIþ): 355.2014, Calcd. for
C21H26N2O3: 355.2016 [MþH]þ.
N-(4-Butylphenyl)-4-methoxy-3-propionamidobenzamide (24): a
white solid; yield: 82%. m.p: 165–168 1C. 1H NMR (400 MHz,
DMSO-d6): δ 10.02 (s, 1H), 9.18 (s, 1H), 8.50 (s, 1H), 7.74 (dd,
J¼8.6, 2.2 Hz, 1H), 7.66–7.63 (m, 2H), 7.15 (d, J¼8.6 Hz, 3H),
3.91 (s, 3H), 2.55 (t, J¼8.0 Hz, 2H), 2.42 (q, J¼8.0 Hz, 2H),
1.591.51 (m, 2H), 1.31 (m, 2H), 1.09 (t, J¼8.0 Hz, 3H), 0.91
(t, J¼8.0 Hz, 3H). 13C NMR (101 MHz, DMSO-d6): δ 172.52,
165.35, 151.76, 137.80, 137.46, 128.73, 127.50, 127.39, 124.57,
122.63, 120.85, 110.86, 56.45, 34.73, 33.69, 29.63, 22.16, 14.26,
10.19. HR-MS (ESIþ): 355.2014, Calcd. for C21H26N2O3:
355.2016 [MþH]þ.
N-(4-Cyclohexylphenyl)-4-methoxy-3-propionamidobenzamide
(25): a white solid, yield: 78%. m.p: 167–169 1C. 1H NMR
(400 MHz, DMSO-d6): δ 10.01 (s, 1H), 9.18 (s, 1H), 8.50
(s, 1H), 7.73 (dd, J¼8.6, 2.2 Hz, 1H), 7.66–7.64 (m, 2H), 7.19–
7.14 (m, 3H), 3.91 (s, 3H), 2.42 (m, 3H), 1.79 (d, J¼10.5 Hz,
4H), 1.71 (m, 1H), 1.4 –1.37 (m, 4H), 1.281.25 (m, 1H), 1.09
(t, J¼7.5 Hz, 3H). 13C NMR (101 MHz, DMSO-d6): δ 172.72,
165.35, 143.18, 137.56, 127.51, 127.39, 127.06, 124.58, 122.63,
120.90, 110.84, 56.45, 43.71, 34.54, 29.63, 26.85, 26.09, 10.19.
HR-MS (ESIþ): 381.2171, Calcd. for C23H29N2O3: 381.2172
[MþH]þ.
N-(4-Cyanophenyl)-4-methoxy-3-propionamidobenzamide (26):
a white solid, yield: 75%. m.p: 154–157 1C. 1H NMR (400 MHz,
DMSO-d6): δ 10.51 (s, 1H), 9.22 (s, 1H), 8.56 (s, 1H), 8.017.98
(m, 2H), 7.837.81 (m, 2H), 7.78 (dd, J¼8.6, 2.2 Hz, 1H), 7.20
(d, J¼8.7 Hz, 1H), 3.94 (s, 3H), 2.44 (q, J¼7.5 Hz, 2H), 1.08
(s, 3H). 13C NMR (101 MHz, DMSO-d6): δ 172.82, 166.11,
153.20, 144.23, 133.51, 127.68, 126.56, 125.01, 122.64, 120.62,
119.62, 110.95, 105.45, 56.53, 29.64, 10.17. HR-MS (ESIþ):
324.1340, Calcd. for C18H17N3O3: 324.1342 [MþH]þ.
N-(4-(4-Methylpiperazin-1-yl)phenyl)-4-methoxy-3-propionami-
dobenzamide (27): a white solid, yield: 65%, m.p: 161–164 1C. 1H
NMR (400 MHz, DMSO-d6): δ 10.91 (s, 1H), 9.99 (s, 1H), 9.18
(s, 1H), 8.50 (s, 1H), 7.75 (dd, J¼8.6, 2.0 Hz, 1H), 7.65
(d, J¼9.0 Hz, 2H), 7.14 (d, J¼8.7 Hz, 1H), 6.99 (d, J¼9.0 Hz,
2H), 3.91 (s, 3H), 3.343.26 (m, 8H), 2.80 (s, 3H), 2.42
(q, J¼7.4 Hz, 2H), 1.09 (t, J¼7.5 Hz, 3H). 13C NMR
(101 MHz, DMSO-d6): δ 172.73, 165.11, 152.75, 146.20,
132.75, 127.47, 127.38, 124.54, 122.64, 121.98, 116.68, 110.84,
56.46, 52.57, 46.41, 42.43, 29.63, 10.20. HR-MS (ESIþ):
397.2231, Calcd. for C22H28N4O3: 397.2234 [MþH] þ.4.1.3. General procedure for the synthesis of compounds 28–34
To the intermediates 13–19 (2.0 mmol) in CH3OH (20 mL) was
added 10% dry Pd/C (0.01 mmol) and 40% HCHO solution
(3.0 mmol), and the mixture was stirred under hydrogen for 4 h.
The catalyst was ﬁltered off and the combined organic solutions
were concentrated under reduced pressure. The residue waspuriﬁed by column chromatography (PE/EA¼10:1, v/v) to afford
compounds 28–34.
N-(3-Chlorophenyl)-4-methoxy-3-(methylamino)benzamide
(28): a white solid, yield: 50%. m.p: 143–144 1C. 1H NMR
(400 MHz, DMSO-d6): δ 10.11 (s, 1H), 7.96 (t, J¼2.0 Hz, 1H),
7.72 (dd, J¼8.3, 1.0 Hz, 1H), 7.37 (t, J¼8.1 Hz, 1H), 7.26 (dd,
J¼8.2, 2.1 Hz, 1H), 7.17–7.07 (m, 1H), 7.02 (d, J¼2.1 Hz,1H),
6.91 (d, J¼8.3 Hz, 1H), 5.25 (s, 1H), 3.86 (s, 3H), 2.79
(d, J¼5.1 Hz, 3H). 13C NMR (101 MHz, DMSO-d6): δ 166.52,
149.74, 141.51, 139.52, 133.32, 130.66, 127.56, 123.33, 120.08,
119.00, 116.23, 109.01, 107.85, 56.04, 30.19. HR-MS (ESIþ):
291.0895, Calcd. for C15H15N2O2Cl: 291.0894 [MþH] þ.
N-(4-Ethylphenyl)-4-methoxy-3-(methylamino)benzamide (29):
a white solid, yield: 67%. m.p: 156–157 1C. 1H NMR (400 MHz,
DMSO-d6): δ 9.88 (s, 1H), 7.66 (d, J¼8.5 Hz, 2H), 7.26 (dd,
J¼8.3, 2.1 Hz, 1H), 7.17 (d, J¼8.5 Hz, 2H), 7.04 (d, J¼2.1 Hz,
1H), 6.89 (d, J¼8.3 Hz, 1H), 5.21 (q, J¼5.0 Hz, 1H), 3.85 (s,
3H), 2.79 (d, J¼5.0 Hz, 3H), 2.58 (q, J¼7.6 Hz, 2H), 1.18 (t,
J¼7.6 Hz, 3H). 13C NMR (101 MHz, DMSO-d6): δ 166.09,
149.45, 139.43, 139.07, 137.64, 128.15, 128.10, 120.93, 116.04,
108.96, 107.92, 56.00, 30.22, 28.09, 16.21. HR-MS (ESIþ):
285.1597, Calcd. for C17H20N2O2: 285.1597 [MþH] þ.
N-(4-iso-propylphenyl)-4-methoxy-3-(methylamino)benzamide
(30): a white solid, yield: 60%. m.p: 166–167 1C. 1H NMR
(400 MHz, DMSO-d6): δ 9.88 (s, 1H), 7.71–7.61 (m, 2H), 7.26
(dd, J¼8.3, 2.1 Hz, 1H), 7.20 (d, J¼8.5 Hz, 2H), 7.03
(d, J¼2.1 Hz, 1H), 6.89 (d, J¼8.4 Hz, 1H), 5.20 (m, 1H), 3.85
(s, 3H), 2.86 (m, 1H), 2.79 (d, J¼5.1 Hz, 3H), 1.20 (d, J¼4.0 Hz,
6H). 13C NMR (101 MHz, DMSO-d6): δ 166.08, 149.45, 143.74,
139.43, 137.71, 128.09, 126.65, 120.92, 116.03, 108.95, 107.93,
56.00, 33.36, 30.22, 24.46. HR-MS (ESIþ): 299.1752, Calcd. for
C18H22N2O2: 299.1754 [MþH] þ.
N-(4-tert-Butylphenyl)-4-methoxy-3-(methylamino)benzamide
(31): a white solid, yield: 69%. m.p: 145–146 1C. 1H NMR
(400 MHz, DMSO-d6): δ 9.89 (s, 1H), 7.747.60 (m, 2H),
7.427.31 (m, 2H), 7.27 (dd, J¼8.3, 2.1 Hz, 1H), 7.04 (d,
J¼2.1 Hz, 1H), 6.89 (d, J¼8.4 Hz, 1H), 5.21 (q, J¼4.7 Hz, 1H),
3.86 (s, 3H), 2.79 (d, J¼5.0 Hz, 3H), 1.29 (s, 9H). 13C NMR
(101 MHz, DMSO-d6): δ 166.09, 149.46, 145.98, 139.44, 137.39,
128.08, 125.54, 120.58, 116.04, 108.94, 107.94, 56.00, 34.48,
31.70, 30.23. HR-MS (ESIþ): 313.1906, Calcd. for C19H24N2O2:
313.1910 [MþH] þ.
N-(4-Butylphenyl)-4-methoxy-3-(methylamino)benzamide (32):
a white solid, yield: 60%. m.p: 160–162 1C. 1H NMR
(500 MHz, DMSO-d6): δ 9.89 (s, 1H), 7.65 (d, J¼8.5 Hz, 2H),
7.25 (dd, J¼8.3, 2.1 Hz, 1H), 7.14 (d, J¼8.5 Hz, 2H), 7.02
(d, J¼2.1 Hz, 1H), 6.89 (d, J¼8.4 Hz, 1H), 5.23 (m, 1H), 3.85
(s, 3H), 2.78 (d, J¼5.1 Hz, 3H), 2.55 (t, J¼7.6 Hz, 2H),
1.581.52 (m, 2H), 1.33–1.29 (m, 2H), 0.90 (t, J¼7.4 Hz, 3H).
13C NMR (101 MHz, DMSO-d6): δ 166.09, 149.44, 139.43,
137.62, 128.68, 128.11, 120.87, 116.02, 108.97, 107.91, 56.00,
34.73, 33.70, 30.22, 22.17, 14.27. HR-MS (ESIþ): 313.1907,
Calcd. for C19H24N2O2: 313.1910 [MþH] þ.
N-(4-Cyclohexylphenyl)-4-methoxy-3-(methylamino)benzamide
(33): a white solid, yield: 65%. m.p: 165–167 1C. 1H NMR
(500 MHz, DMSO-d6): δ 9.87 (s, 1H), 7.667.64 (m, 2H), 7.25
(dd, J¼8.3, 2.1 Hz, 1H), 7.17 (d, J¼8.5 Hz, 2H), 7.02
(d, J¼2.1 Hz, 1H), 6.89 (d, J¼8.4 Hz, 1H), 5.21 (m, 1H), 3.85
(s, 3H), 2.78 (d, J¼5.1 Hz, 3H), 2.46 (s, 1H), 1.79 (m, 4H), 1.71
(m, 1H), 1.41.31 (m, 4H), 1.22 (m, 1H). 13C NMR (101 MHz,
DMSO-d6): δ 166.08, 149.44, 143.01, 139.43, 137.73, 128.11,
127.01, 120.89, 116.03, 108.96, 107.92, 56.00, 43.70, 34.56,
N-phenylbenzamide and N-phenylacetophenone compounds as anti-HCV and anti-EV71 agents 20730.22, 26.86, 26.09. HR-MS (ESIþ): 339.2065, Calcd. for
C21H27N2O2: 339.2067 [MþH]þ.
N-(4-Cyanophenyl)-4-methoxy-3-(methylamino)benzamide (34):
a white solid, yield: 73%. m.p: 165–167 1C. 1H NMR (400 MHz,
DMSO-d6): δ 10.36 (s, 1H), 8.017.97 (m, 2H), 7.827.79 (m,
2H), 7.28 (dd, J¼8.3, 2.2 Hz, 1H), 7.02 (d, J¼2.1 Hz, 1H), 6.93
(d, J¼8.4 Hz, 1H), 5.28 (m, 1H), 3.87 (s, 3H), 2.78 (t, J¼7.8 Hz,
3H). 13C NMR (101 MHz, DMSO-d6): δ 166.87, 149.94, 144.38,
139.57, 133.50, 127.35, 120.52, 119.66, 116.44, 109.01, 107.88,
105.26, 56.07, 30.17. HR-MS (ESIþ): 282.1236, Calcd. for
C16H15N3O2: 282.1237 [MþH]þ.4.1.4. General procedure for the synthesis of compounds 35–36
To a solution of 21 or 23 (1.0 mmol) in DCM (20 mL) was added
BBr3 (1.2 mmol) in DCM (5 mL) over 15 min at 78 1C. The
resulting solution was allowed to warm to 25 1C and stirred for
2 h. The reaction was quenched with saturated aqueous NH4Cl,
extracted with DCM (20 mL 3), and washed with brine. The
combined organic layers were dried with Na2SO4 and concentrated
under reduced pressure. The residue was puriﬁed by column
chromatography (PE/EA¼10:1, v/v) to give 35–36.
N-(4-Chlorophenyl)-4-hydroxy-3-propionamidobenzamide (35):
a white solid, yield: 34%. m.p: 179–181 1C. 1H NMR (400 MHz,
DMSO-d6): δ 10.55 (s, 1H), 10.15 (s, 1H), 9.31 (s, 1H), 8.36
(d, J¼1.2 Hz, 1H), 7.827.78 (m, 2H), 7.62 (dd, J¼8.4, 2.0 Hz,
1H), 7.417.37 (m, 2H), 6.96 (d, J¼8.4 Hz, 1H), 2.43
(q, J¼7.5 Hz, 2H), 1.10 (t, J¼7.5 Hz, 3H). 13C NMR
(101 MHz, DMSO-d6): δ 173.17, 165.73, 138.91, 128.90,
127.31, 126.61, 125.76, 125.00, 123.18, 122.20, 115.48, 40.19,
39.77, 39.35, 29.54, 10.21. HR-MS (ESIþ): 319.0842, Calcd. for
C16H15N2O3Cl: 319.0844 [MþH]þ.
N-(4-tert-Butylphenyl)-4-hydroxy-3-propionamidobenzamide (36):
a white solid, yield: 40%. m.p: 182–184 1C. 1H NMR
(400 MHz, DMSO-d6): δ 10.46 (s, 1H), 9.95 (s, 1H), 9.32
(s, 1H), 8.33 (s, 1H), 7.657.61 (m, 3H), 7.35 (d, J¼8.6 Hz,
2H), 6.95 (d, J¼8.4 Hz, 1H), 2.43 (m, 2H), 1.28 (s, 9H), 1.10
(t, J¼7.5 Hz, 3H). 13C NMR (101 MHz, DMSO-d6): δ 173.18,
165.44, 151.60, 146.05, 137.30, 126.50, 126.21, 125.58, 124.92,
123.26, 120.53, 115.48, 34.49, 31.69, 29.52, 10.22. HR-MS
(ESIþ): 341.1859, Calcd. for C20H25N2O3: 341.1859 [MþH]þ.4.1.5. General procedure for the synthesis of 39, 40
To a solution of 37 or 38 (3.6 mmol) in DCM (30 mL) and DMF
(5 mL) was added DIC (4.3 mmol), HOBt (4.3 mmol) and aniline
(3.8 mmol). After the mixture was stirred at room temperature for
24 h, the reaction was extracted with DCM (20 mL 3), and
washed with brine. The combined organic layers were dried over
Na2SO4 and concentrated under reduced pressure. The residue was
puriﬁed by column chromatography (PE/EA¼5:1, v/v) to give 39
or 40.4.1.6. General procedure for the synthesis of 41 or 43
To a solution of 39 or 40 (2.0 mmol) in DCM (30 mL) was added
TEA (2.0 mmol), and then the solution of propionyl chloride
(3.0 mmol) was added slowly. After the mixture was stirred at
room temperature for 3 h, the reaction was extracted with DCM
(20 mL 3), and washed with brine. The combined organic layers
were dried over Na2SO4 and concentrated under reduced pressure.
The residue was puriﬁed by column chromatography (PE/EA
¼10:1, v/v) to give 41 or 43.N-(4-Chlorophenyl)-3-propionamidobenzamide (41): a white
solid, yield: 80%. m.p: 160–163 1C. 1H NMR (400 MHz,
DMSO-d6): δ 10.38 (s, 1H), 10.08 (s, 1H), 8.10 (s, 1H), 7.83
(m, 3H), 7.60 (d, J¼7.8 Hz, 1H), 7.44 (m, 3H), 2.35 (q, J¼7.5
Hz, 2H), 1.10 (t, J¼7.5 Hz, 3H). 13C NMR (101 MHz, DMSO-
d6): δ 172.70, 166.17, 140.02, 138.62, 135.88, 129.21, 129.00,
127.69, 122.52, 122.32, 122.25, 118.95, 29.98, 10.07. HR-MS
(ESIþ): 303.0893, Calcd. for C16H15N2O2Cl: 303.0894 [MþH]þ.
N-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-4-methyl-3-propiona-
midobenzamide (43): a white solid, yield: 77%. m.p: 167–168 1C.
1H NMR (400 MHz, DMSO-d6): δ 10.02 (s, 1H), 9.42 (s, 1H),
7.94 (s, 1H), 7.68 (dd, J¼7.9, 1.6 Hz, 1H), 7.38 (d, J¼2.4 Hz,
1H), 7.34 (d, J¼8.0 Hz, 1H), 7.20 (dd, J¼8.8, 2.5 Hz, 1H), 6.82
(d, J¼8.7 Hz, 1H), 5.76 (s, 1H), 4.23 (q, J¼5.0 Hz, 4H), 2.38
(q, J¼7.6 Hz, 2H), 2.26 (s, 3H), 1.12 (t, J¼7.6 Hz, 3H). 13C
NMR (101 MHz, DMSO-d6): δ 172.60, 165.14, 143.23, 140.01,
137.04, 136.32, 133.33, 133.17, 130.55, 125.19, 124.60, 117.01,
114.14, 109.98, 64.53, 29.35, 18.47, 10.40. HR-MS (ESIþ):
341.1494, Calcd. for C19H20N2O4: 341.1495 [MþH]þ.4.1.7. General procedure for the synthesis of compounds 42 or 44
To a solution of 39 or 40 (2.0 mmol) in acetone (15 mL) was
added K2CO3 (3.0 mmol) and CH3I (5.00 mmol), and then the
resulting solution was stirred at 50 1C for 10 h. The mixture was
cooled to ambient temperature and the solvent was removed under
reduced pressure. The residue was dissolved in DCM (35 mL), and
washed with brine. The organic layers were dried over Na2SO4
and concentrated under reduced pressure. The residue was puriﬁed
by column chromatography (PE/EA¼10:1, v/v) to afford 42 or 44.
N-(4-Chlorophenyl)-3-(methylamino)benzamide (42): a white
solid, yield: 45%. m.p: 164–167 1C. 1H NMR (400 MHz, CDCl3):
δ 7.76 (s, 1H), 7.60 (d, J¼8.8 Hz, 2H), 7.33 (d, J¼8.8 Hz, 2H),
7.12 (s, 1H), 7.07 (d, J¼7.6 Hz, 1H), 6.78 (dd, J¼8.1, 2.1 Hz,
1H), 2.90 (s, 3H). 13C NMR (151 MHz, DMSO-d6): δ 166.92,
150.38, 138.79, 136.08, 129.29, 128.92, 127.47, 122.22, 115.31,
115.01, 110.93, 30.17. HR-MS (ESIþ): 261.0789, Calcd. for
C14H13N2OCl: 261.0789 [MþH]þ.
N-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-4-methyl-3-(methyla-
mino)benzamide (44): a white solid, yield: 77%. m.p: 170–173 1C.
1H NMR (400 MHz, DMSO-d6): δ 9.85 (s, 1H), 7.39 (d, J¼2.4
Hz, 1H), 7.19 (dd, J¼8.8, 2.4 Hz, 1H), 7.10 (m, 2H), 6.98
(d, J¼1.0 Hz, 1H), 6.81 (d, J¼8.7 Hz, 1H), 5.24 (q, J¼4.9 Hz,
1H), 4.23 (m, 4H), 2.80 (d, J¼4.9 Hz, 3H), 2.13 (s, 3H). 13C
NMR (101 MHz, DMSO-d6): δ 166.31, 147.99, 143.24, 139.86,
134.11, 133.52, 129.63, 125.86, 116.99, 115.17, 114.05, 109.89,
107.73, 64.64, 64.41, 30.52, 23.76. HR-MS (ESIþ): 299.1388,
Calcd. for C17H18N2O3: 299.1390 [MþH]þ.
N-(5-(2-Bromoacetyl)-2-methoxyphenyl)propionamide (48): to a
solution of 45 (1.0 mmol) in CH3OH (15 mL) was added 10% dry
Pd/C (0.01 mmol), the mixture was reacted with hydrogen (40 psi)
for 4 h. The catalyst was ﬁltered off and the combined organic
solutions were concentrated under reduced pressure. The residue
was dissolved in DCM (25 mL) followed by the addition of TEA
(1.0 mmol), and then a solution of propionyl chloride (1.5 mmol)
was added slowly. After the mixture was stirred at room
temperature for 3 h, the reaction mixture was extracted with
DCM (20 mL 3), and washed with brine. The combined organic
layers were dried over Na2SO4 and concentrated under reduced
pressure. The residue 47 (1.5 mmol) was dissolved in CCl4
(25 mL) followed by the addition of NBS (1.2 mmol) and
p-TSA (0.01 mmol). After the mixture was reﬂuxed for 5 h, the
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was quenched with saturated aqueous NH4Cl (30 mL), extracted
with DCM (20 mL 3), and washed with brine. The combined
organic layers were dried over Na2SO4 and concentrated under
reduced pressure. The residue was puriﬁed by column chromato-
graphy (PE/EA¼10:1, v/v) to give 48: a white solid, yield: 70%.
m.p: 101–103 1C. 1H NMR (400 MHz, CDCl3): δ 9.37 (s, 1H),
8.22 (d, J¼2.0 Hz, 1H), 7.68 (dd, J¼8.9, 2.0 Hz, 1H), 7.12
(d, J¼8.7 Hz, 1H), 4.72 (s, 2H), 3.92 (s, 3H), 2.71 (q, J¼7.7 Hz,
2H), 1.21 (t, J¼7.9 Hz, 3H). ESI-MS (m/z): 300.1 [MþH]þ.4.1.8. General procedure for the synthesis of 49 or 50
To a solution of 48 (0.5 mmol) in ethanol (15 mL) was added
NaHCO3 (1.0 mmol) and aniline (0.55 mmol). After the mixture
was stirred at room temperature for 24 h, the solvent was removed
under reduced pressure. The residue was extracted with DCM
(20 mL 3), and washed with brine. The combined organic layers
were dried over Na2SO4 and concentrated under reduced pressure.
The residue was puriﬁed by column chromatography (PE/EA¼
10:1, v/v) to give 49 or 50.
N-(2-Methoxy-5-(2-(p-tolylamino)acetyl)phenyl)propionamide
(49): a yellow solid, yield: 34%. m.p: 132–134 1C. 1H NMR
(500 MHz, DMSO-d6): δ 9.23 (s, 1H), 8.62 (s, 1H), 7.91 (dd,
J¼8.6, 1.8 Hz, 1H), 7.17 (d, J¼8.7 Hz, 1H), 6.90 (d, J¼8.1 Hz,
2H), 6.58 (d, J¼8.3 Hz, 2H), 5.59 (t, J¼5.3 Hz, 1H), 4.55 (d,
J¼5.4 Hz, 2H), 3.94 (s, 3H), 2.43 (q, J¼7.5 Hz, 2H), 2.15 (s,
3H), 1.08 (t, J¼7.5 Hz, 3H). 13C NMR (101 MHz, DMSO-d6): δ
195.62, 172.91, 154.21, 146.33, 129.72, 128.11, 128.04, 125.81,
124.94, 113.04, 111.14, 56.61, 50.17, 29.64, 20.55, 10.13. HR-MS
(ESIþ): 327.1700, Calcd. for C19H22N2O3: 327.1703 [MþH]þ.
N-(5-(2-((4-(tert-Butyl)phenyl)amino)acetyl)-2-methoxyphenyl)
propionamide (50): yellow solid. yield: 25%. m.p: 130–132 1C.
1H NMR (500 MHz, DMSO): δ 9.24 (s, 1H), 8.63 (s, 1H), 7.91
(dd, J¼8.6, 2.2 Hz, 1H), 7.18 (d, J¼8.7 Hz, 1H), 7.12–7.09 (m,
2H), 6.606.58 (m, 2 H), 5.62 (t, J¼5.4 Hz, 1H), 4.55 (d,
J¼5.5 Hz, 2H), 3.94 (s, 3H), 2.43 (d, J¼7.5 Hz, 2H), 1.22 (s,
9H), 1.08 (t, J¼7.5 Hz, 3H). 13C NMR (101 MHz, DMSO-d6): δ
195.76, 172.91, 154.20, 146.23, 138.80, 128.12, 128.06, 125.87,
125.79, 121.68, 112.67, 111.15, 56.61, 50.12, 33.91, 31.93, 29.65,
10.13. HR-MS (ESIþ): 369.2169, Calcd. for C22H28N2O3:
369.2172 [MþH]þ.4.1.9. General procedure for the synthesis of 52 or 53
To a solution of 45 (0.5 mmol) in CCl4 (15 mL) was added NBS
(0.6 mmol) and p-TSA (0.01 mmol). After the mixture was
reﬂuxed for 5 h, the mixture was cooled to ambient temperature
and then the reaction was quenched with saturated aqueous
NH4Cl (30 mL), extracted with DCM (20 mL 3), and washed
with brine. The combined organic layers were dried over
Na2SO4 and concentrated under reduced pressure. The residue
was puriﬁed by column chromatography (PE/EA ¼10:1, v/v) to
give 51, which was then dissolved in ethanol (25 mL) followed
by the addition of NaHCO3 (1.0 mmol) and anilines (0.55
mmol). After the mixture was stirred at room temperature for
24 h, the solvent was removed under reduced pressure. The
residue was extracted with DCM (20 mL 3), and washed with
brine. The combined organic layers were dried over Na2SO4
and concentrated under reduced pressure. The residue was
puriﬁed by column chromatography (PE/EA¼10:1, v/v) to give
52 or 53.1-(4-Methoxy-3-nitrophenyl)-2-(phenylamino)ethanone (52): a
yellow solid, yield: 79%. ESI-MS (m/z): 287.1 [MþH]þ.
2-((4-Chlorophenyl)amino)-1-(4-methoxy-3-nitrophenyl)etha-
none (53): a yellow solid, yield: 60%. ESI-MS (m/z): 321.0
[MþH]þ.4.1.10. General procedure for the synthesis of 54 or 55
To a solution of 52 or 53 (1.0 mmol) in CH3OH (15 mL) was
added 10% dry Pd/C (0.01 mmol) and 40% HCHO (2.5 mmol).
The mixture was stirred under hydrogen for 4 h. The catalyst was
ﬁltered off and the combined organic solutions were concentrated
under reduced pressure. The residue was puriﬁed by column
chromatography (PE/EA ¼10:1, v/v) to afford 54 or 55.
1-(4-Methoxy-3-(methylamino)phenyl)-2-(phenylamino)ethanone
(54): a yellow solid, yield: 32%. m.p: 135–137 1C. 1H NMR
(500 MHz, DMSO-d6): δ 7.45 (dd, J¼8.3, 1.7 Hz, 1H), 7.08
(t, J¼7.7 Hz, 2H), 7.04 (d, J¼1.5 Hz, 1H), 6.92 (d, J¼8.3 Hz,
1H), 6.68 (d, J¼8.2 Hz, 2H), 6.56 (t, J¼7.2 Hz, 1H), 5.76
(t, J¼5.3 Hz, 1H), 5.32 (q, J¼4.8 Hz, 1H), 4.58 (d, J¼5.4 Hz,
2H), 3.88 (s, 3H), 2.77 (d, J¼5.1 Hz, 3H). 13C NMR (101 MHz,
DMSO-d6): δ 195.94, 151.27, 148.67, 139.79, 129.26, 129.01,
117.81, 116.50, 112.96, 109.09, 106.85, 56.14, 49.72, 30.10.
HR-MS (ESIþ): 271.1440, Calcd. for C16H18N2O2: 271.1441
[MþH]þ.
2-((4-Chlorophenyl)amino)-1-(4-methoxy-3-(methylamino)phe-
nyl)ethanone (55): a yellow solid, yield: 25%. m.p: 140–141 1C.
1H NMR (400 MHz, DMSO-d6): δ 7.44 (dd, J¼8.3, 2.1 Hz, 1H),
7.127.08 (m, 2H), 7.03 (d, J¼2.0 Hz, 1H), 6.92 (d, J¼8.4 Hz,
1H), 6.716.68 (m, 2H), 6.01 (t, J¼5.4 Hz, 1H), 5.30
(q, J¼5.1 Hz, 1H), 4.58 (d, J¼5.4 Hz, 2H), 3.88 (s, 3H), 2.77
(d, J¼5.1 Hz, 3H). 13C NMR (101 MHz, DMSO-d6): δ 195.61,
151.30, 147.70, 139.79, 128.93, 128.90, 119.68, 117.83, 114.34,
109.08, 106.84, 56.14, 49.73, 30.10. HR-MS (ESIþ): 305.1051,
Calcd. for C16H17N2O2Cl: 305.1051 [MþH]þ.4.2. Cells and virus
Huh7.5 human liver cells were kindly provided by Vertex
Pharmaceuticals (Boston, USA), and were cultured in Dulbecco's
Modiﬁed Eagle's Medium, which was supplemented with 10%
inactivated fetal bovine serum and 1% penicillin-streptomycin.
The cells were cultured at 37 1C in 5% CO2, released with 0.05%
trypsin-EDTA and split twice a week. The plasmid pFL-J6/JFH/
JC1, which contains the full-length chimeric HCV cDNA was
kindly provided by Vertex Pharmaceutical (Boston, USA). Vero
cells were purchased from the American Type Culture Collection
and were cultured in Minimum Essential Medium (MEM)
supplemented with 10% fetal bovine serum (FBS) and antibiotics
(100 U/mL penicillin G and 100 mg/mol streptomycin). EV71
strain SZ-98 was kindly provided by Dr Qi Jin, Institute of
Pathogen Biology, Chinese Academy of Medical Sciences and
Peking Union Medical School.4.3. Cytotoxicity assay
The Huh7.5 cells were used in the test; Huh7.5 cells (1 104
cells/well) were planted into 96-microwell plates. Six hours later
the culture media was replaced with fresh medium containing the
tested compounds at various concentrations. Cytotoxicity was
evaluated by the MTT assay at 96 h. The 50% cytotoxic
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method.
The cytotoxic effect of the target compounds on Vero cells was
assayed by the CPE method. Brieﬂy, cells were seeded into 96-
well culture plates (3 104 cells/well) and were incubated over-
night. Then, different concentrations of the test compounds were
applied in triplicate. After incubation for 3 d, Median toxic
concentration (TC50) was deﬁned as the concentration that inhibits
50% cellular growth in comparison with untreated controls and
calculated by the Reed and Muench method.
4.4. Anti-HCV assay
The Huh7.5 cells were seeded into 6-well plates (Costar) at a
density of 3 104 cells/cm2. After 6 h incubation, cells were
infected with HCV viral stock (45 u/cell) and treated simulta-
neously with the test compounds or the control. The culture
medium was removed after 96 h inoculation and the intracellular
total RNA was extracted with RNeasy Mini Kit (Qiagen, Hilden,
Germany). The HCV RNA was quantiﬁed directly with a one-step
RTPCR kit (Invitrogen). The 50% inhibition concentration (IC50)
was calculated with the Reed & Muench method. SI value was
calculated as the ratio of CC50/IC50.
4.5. Anti-EV71 assay
The anti-EV71 activity of the target compounds was also assayed
by the CPE method. Brieﬂy, cells (3 104 cells/well) were plated
into 96-well culture plates. The cells were infected with EV71 of
100TCID50. Then, various concentrations of the test compounds
were supplemented immediately for incubation of another 48 h.
The IC50 was determined by the Reed and Muench method. The SI
value was calculated as the ratio of TC50/IC50.
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